The standard non-invasive treatment of pseudoaneurysms has been ultrasoundguided compression (UGC). Problems with UGC include pain at the site of compression, long compression times and incomplete closure. Each of these difficulties is exacerbated with large pseudoaneurysms. Recently, ultrasound-guided injection of pseudoaneurysms with thrombin has gained popularity. The goal of this study was to report a multicenter registry using this technique and in so doing detail the clinical utility and safety of this emerging procedure. The medical records of all patients diagnosed with pseudoaneurysm in the vascular laboratory who underwent thrombin injection over the past year were reviewed for patient characteristics and clinical outcome. There were 91 patients (55 male) with a mean age of 69 years. Three patients also had an arteriovenous fistula. The majority of patients were receiving one or more antiplatelet agents and/or anticoagulants. All patients underwent pseudoaneurysm injection with bovine thrombin. The mean aneurysm diameter was 3.3 cm, with a range of 1.5-6.3 cm. Successful thrombosis of the pseudoaneurysm was achieved in 89/91 (98%) of cases. Anticoagulation with heparin was used in one of the unsuccessful cases. In two cases, UGC was used to close a small active region that did not completely thrombose after thrombin injection. There were two patients who had recurrence of pseudoaneurysm the day after successful injection and thrombosis of the pseudoaneurysm. There were no local complications after injection; however, one patient suffered a pulmonary embolus that was thought to be unrelated to the procedure. In conclusion, thrombin injection for the treatment of pseudoaneurysms is safe and effective, even in patients receiving anticoagulation. This procedure should be considered as the initial therapeutic approach for peripheral pseudoaneurysms.
Introduction
As the number of catheter-based, interventional procedures, including cardiac catheterization and electrophysiologic study, increase, the diagnosis of insertion-site pseudoaneurysm (PSA) is becoming more common. A PSA is defined as an arterial rupture of one or more layers of its walls, contained by overlying fibromuscular tissue, which communicates with an artery by a neck or sinus tract. 1 The acute PSA is essentially a contained, pulsatile hematoma, whereas over time the chronic PSA develops a thicker fibrous wall with an endothelial layer. The incidence of PSA formation as a complication of percutaneous coronary angioplasty approximates between 0.5% and 6.3% of procedures and 2.6% of 'new device' coronary angioplasty procedures. 2 During the 1990s, ultrasound-guided compression was the initial treatment of choice for PSAs. 3, 4 Although ultrasound-guided compression is ultimately suc-cessful in up to 90% of patients with extended compression times up to 120 min, there are several disadvantages to this technique. These disadvantages include patient discomfort, muscular discomfort on the part of the staff carrying out the procedure, prolonged use of ultrasound equipment, early recurrence of PSA, and limited success in treating large PSAs or patients requiring anticoagulation. 4, 5 Recently, single-center prospective studies were published indicating that percutaneous ultrasound injection of thrombin into PSAs is safe and effective. [6] [7] [8] [9] [10] [11] [12] However, a multicenter experience evaluating the effectiveness of this emerging technique is lacking. Accordingly, we are reporting a multicenter registry detailing the safety and efficacy of percutaneous ultrasound-guided and thrombin injection to treat PSAs. A registry allows for a large number of cases and insight into the various approaches from multiple centers as well as potential complications of this procedure.
Methods
This study was conducted from January 1999 to March 2000 at four sites, including the Brigham and Woman's Hospital, Boston, MA, University of Pennsylvania, Philadelphia, PA, University of Washington, Seattle, WA and the Washington Hospital Center, Washington, DC. The data registry was maintained at the University of Pennsylvania School of Medicine. These institutions have academic affiliations and see a high number of patients (Ͼ3000 per year) in the vascular laboratory. The study was approved by the Institutional Review Boards for each institution and each patient signed informed consent for the procedure. The medical records of consecutive patients diagnosed with PSA in the vascular laboratories were reviewed for patient characteristics and clinical outcome, and the results were recorded in an Excel database. A total of 91 consecutive patients, of whom 55 were male, with a mean age of 69 years (range 24-87 years), were entered into the study.
The technique of thrombin injection with a 21-gauge needle was the most commonly used in conjunction with saline injection to identify the tip of the needle. An ultrasound-opaque needle was used alone on occasion in some centers. In addition, one center 'scored' the tip of the needle with a sterile 11-gauge scalpel to increase the echogenicity of the needle tip. Variations in the technique include thrombin dose, single or double syringes, and monitoring of the patient. 6, 7, 9, 13 Patients typically received 500-1000 U of bovine thrombin after the echogenic needle was visualized within the cavity and blood aspirated.
Diagnostic duplex ultrasound was performed with a 5-MHz linear array transducer on a Hewlett Packard/Agilent Technologies 5500 (Andover, MA, USA), Acuson XP (Mountain View, CA, USA), or an ATL (Bothell, WA, USA) ultrasound machine. Ultrasonography was performed before and after thrombin injection to determine arterial and venous patency. Patients were not included or excluded due to neck size or sac size.
Ultrasound-guided percutaneous thrombin injection was performed in 91 patients with PSA. The mean maximum diameter of the active PSA sac was 3.3 cm with a range of 1.5-6 cm. There were 74 PSAs originating from the common femoral artery, 11 from the superficial femoral artery and six from the profunda femoris artery. Three patients had arteriovenous fistulae. All patients, except for one that was receiving warfarin, were receiving at least one antiplatelet agent. Ten patients received both aspirin and clopidogrel and one patient received intravenous IIbIIIa receptor inhibitor. All patients received direct injection of bovine thrombin into the PSA cavity using a 21-22-gauge needle attached to a Becton Dickinson syringe (21 patients), or to a three-way stopcock with normal saline in the second syringe (31 patients). PSA formation occurred after cardiac catheterization in 74 patients, after a peripheral angiography in 13, after a dialysis access catheter removal in one, with lower extremity bypass grafts in two, and postoperatively after coronary artery bypass surgery in one (Table  1) . 
Results
The initial success rate, defined as complete thrombosis of the sac with one injection, was 96% (n = 87). A second injection was necessary in three patients and one patient required three injections of thrombin. When successful, thrombin injection results in almost instantaneous thrombosis of the sac as documented by the disappearance of the color flow Doppler signal. There were seven PSAs with multiple lobes (Figure 1 ). For these, the most successful approach was injection of the sac in close proximity to the skin followed by injections of the deeper sacs, if necessary. Two patients required a brief ultrasound-guided compression to close a small active region that remained despite thrombin injection. One of these two patients was treated with heparin (PTT 72 s). There were two PSAs that did not thrombose with injection of thrombin. One of these two patients was anticoagulated with heparin (PTT 76) as well as aspirin and clopidogrel. The other patient complained of groin pain after a second injection of thrombin and no further injections were attempted. However, this patient had successful ultrasoundguided compression of the PSA the next day. Of note, there were seven patients treated successfully with thrombin injection while on the combination of heparin, clopidogrel and aspirin.
There were no local complications after thrombin injection. One patient suffered a pulmonary embolus shortly after the procedure. This patient did not have an arteriovenous fistula or deep vein thrombosis in the ipsilateral femoral veins. Although a causative role for the thrombin injection cannot be absolutely excluded, the pulmonary embolus was probably not directly related to the procedure because subsequent surgical thrombectomy revealed bone marrow cells and bone fragments within the center of the thrombus. This suggests that the thrombus formed at the time of bone fracture rather than at the time of thrombin injection. The patient had undergone sternotomy at the time of coronary artery bypass graft surgery. There was no fracture associated with the thrombin injection.
Discussion
An acute PSA is an arterial rupture contained by fibromuscular tissue that communicates with the artery via a narrow neck. The non-invasive treatment of a PSA is expanding with the success of non-surgical closure strategies. This study details a multicenter registry experience of thrombin injection for treatment of PSAs. Several single-center reports indicate that this technique is safe and effective for the treatment of PSAs. [6] [7] [8] [10] [11] [12] [13] [14] [15] [16] [17] [18] Our study extends this single-center experience by providing information on safety and efficacy from multiple sites. The results from this study indicate that thrombin injection is effective for treating PSAs resulting from surgical graft complications.
The treatment of PSA before 1985 was surgical repair but this procedure is not without potential complications. 19 Reports of the natural history of unrepaired PSA indicate that spontaneous closure can occur, especially with smaller PSA. A large size (Ͼ3 cm), symptomatic, expanding, or those associated with large hematomas are generally thought the most prone to rupture. 20, 21 However, it is impossible to predict which of the smaller PSA will rupture and a PSA can rupture even after successful ultrasoundguided compressive therapy. 5 Cope and Zeit pioneered the technique of injection with thrombin for iliac, femoral, and peroneal arteries PSA, as well as injection of a true aneurysm of the hepatic artery. 22, 23 The common reported dose of thrombin ranges from 500 to 2000 U. Based on the results from animal studies 24, 25 and the thrombin dose reported for intravascular treatment of esophageal 26 and gastric 27 varices, thrombin injection of 0.5-2 ml at 1000 U/ml is considered a safe and effective dose range. 7 Several methods of thrombin injection have been reported in the literature. 8, 9 The technique of thrombin injection with a 21-gauge needle is most commonly used in conjunction with saline injection to identify the tip of the needle; however, an ultrasound opaque needle may also be used alone. In addition, 'scoring' the tip of the needle with a sterile 11-gauge scalpel can markedly increase the echogenicity of the needle tip. Variations in the technique include thrombin dose, single or double syringes, and monitoring of the patient. In our series, patients typically received 500-1000 U of bovine thrombin after the echogenic needle was visualized within the cavity and blood aspirated. The majority of injections occurred in the vascular laboratory while the patients' hemodynamic status and pulses were monitored closely. In all cases, at least two people were present and necessary to allow simultaneous visualization and injection of the PSA.
Sheiman et al reported that complex PSAs usually required more than one injection of thrombin and a total thrombin dose of at least 1500 U. The registry results reported here also indicate that almost all PSA with more than one sac will require multiple injections of thrombin. Unlike the report of Sheiman and Brophy 10 , some of the PSA with two sacs were successfully treated with two 500 U injections and thus Ͼ1000 U of thrombin were not always needed. Our registry experience also indicates that the preferred approach for treating PSA with multiple sacs is initial injection of the sac closest to the skin followed Vascular Medicine 2001; 6: 241-244 by injections of the deeper sacs, although this approach would be better proven with a prospective study.
There are several potential benefits of this technique. The rapid thrombosis of the PSA after injection is better tolerated than compression, which may take up to 2 h. 28 Further, blood loss and the risk of general anesthesia attendant with surgical repair are avoided. In addition, success rates are superior to compression, decreasing the likelihood of repeated study and treatment.
In order to maximize the safety and efficacy of this technique, physicians and technicians should be comfortable with ultrasonography and obtaining vascular access. Although no serious adverse event attributable to the procedure was noted in this series, emergency resuscitation procedures should be available prior to attempting the procedure given the frequent cardiovascular comorbidites that tend to occur in the patient population. Further, special care must be used to avoid thrombin injection into an artery or vein, as can occur with an arteriovenous fistula, non-visualized PSA neck, and wide PSA neck (Ͼ1 cm). Patients with evidence of skin necrosis, skin infection, or symptomatic PSAs should receive a surgical referral.
In summary, this is the first reported multicenter registry of bovine thrombin injection of PSA confirming the efficacy of this approach in the monitored setting by appropriate personnel. As experience with and use of this technique increases, rapid diagnosis and treatment of postcatheterization PSAal disease will become feasible.
